Dr. Reddy’s Laboratories Shares Decline Amid Market Volatility
On October 29, 2025, Dr. Reddy’s Laboratories’ stock experienced a significant decline, closing at ₹1,250.90 on the National Stock Exchange (NSE), marking a 2.99% drop from the previous close of ₹1,289.40. The day’s trading saw the stock reach a low of ₹1,235 and a high of ₹1,301.50, reflecting heightened market volatility.
Recent Market Performance
Over the past week, Dr. Reddy’s shares have underperformed compared to the broader market. The stock declined by 3.67%, while the Sensex rose by 0.64% during the same period. Year-to-date, the company’s shares have fallen by 10.79%, indicating ongoing challenges in maintaining investor confidence.
Analyst Perspectives
Analysts have expressed concerns regarding Dr. Reddy’s future performance. Citi Research maintained a ‘sell’ rating on the stock, lowering its target price to ₹990, suggesting a potential downside of over 26% from the current levels. The brokerage highlighted challenges such as declining sales of key products like Revlimid and the expiration of production-linked incentives, which could impact the company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) by approximately $750–780 million.
Strategic Developments
In an effort to strengthen its portfolio, Dr. Reddy’s announced a definitive agreement with Johnson & Johnson’s affiliate, Janssen Pharmaceutica NV, to acquire the Stugeron brand for $50.5 million (approximately ₹445 crore). This acquisition includes leading brands such as Stugeron FORTE and Stugeron PLUS, expanding Dr. Reddy’s presence in the anti-vertigo therapeutic segment across 18 markets, including India and Vietnam.
Regulatory Challenges
The United States Food and Drug Administration (USFDA) completed an inspection of Dr. Reddy’s formulations manufacturing facility in Srikakulam, Andhra Pradesh, from July 10 to 18, 2025. The inspection resulted in a Form 483 with seven observations, which the company has committed to addressing within the stipulated timeline. Such regulatory scrutiny may influence investor sentiment and the company’s operational strategies.
As Dr. Reddy’s Laboratories navigates these market dynamics, investors are advised to monitor the company’s strategic initiatives and regulatory responses closely to assess potential impacts on its financial performance and stock valuation.
